Skip to main content

Cell therapy unit (Hematology)

The hematological cell therapy unit (U.T.C.H.) is a platform dedicated to translating new cell therapies into reliable and effective treatment that increases the survival rate of cancer patients as a result of innovative approaches. The unit's functioning is closely integrated with that of the apheresis unit upstream and the clinical transplantation service downstream. It also cooperates with the translational research units in developing new cellular products for clinical usage. We provide the Institute as a whole with the expertise that is essential for implementing and developing cellular immunotherapy. 

The cell therapy platform is a unit that complies with GMP standards for the collecting, processing (including selection, expansion, freezing, etc. of cells), control, storage and delivery of several cell types, including hematopoietic stem cells,  mesenchymal cells, lymphocytes and dendritic cells. It has three banks with FAMHP   (Federal Agency for Medicines and Health Products) accreditation: the hematopoietic stem cell bank, the  therapeutic cell bank, accredited since 2009, under the inspection programme  (Joint Accreditation Committee of the ISCT and EBMT or JACIE), and the ULB's umbilical cord blood bank, accredited by the US agency FACT ((Foundation for Accreditation of Cellular Therapy). Our accreditations certify work that complies with high quality standards and enable us to continuously improve quality within the various teams involved in carrying out hematopoietic transplants and in cellular therapy in general. 

Our expertise has also enabled us to develop close cooperation with small biotech companies active in developing innovative therapies. We provide them with the opportunity to benefit from professional services ranging from access to an accredited cell therapy unit when carrying out their clinical trials to the services of consultants when optimising new products. 

Given the dramatic growth of immunotherapy the Institute has also decided to invest in a huge unit complying with GMP standards in its new buildings at the New Bordet. This new unit should enable us to meet the challenge of new cellular immunotherapies and to meet the needs both of the Institute and of its potential academic and private collaborators. 

Research projects


 

Project 1

CAR-T cell therapy implementation

Project 2

A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A SINGLE DOSE OF AUTOLOGOUS CRISPR-CAS9 MODIFIED CD34+ HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS (CTX001) IN SUBJECTS WITH SEVERE SICKLE CELL DISEASE

Our team

Head of the Department of Hematology
Pr Nathalie Meuleman

Director of the Cell Therapy Unit and Banks Manager
Pr Philippe Lewalle

Scientific Director of the Cell Therapy UnitRedouane Rouas

Cell Therapy Unit Qualitician
Aurélie Timmermans
- Sfia Bourdji

Technicians at the Cell Therapy Unit
- Marie-José Concepcion Caballero
- Christine Dorval
- Pierrick Luystermans
- Triantafillia Stamopulos
- Sarah Cela

Secretariat
- Vanessa Vanpevenage

10/02/2022

 Scientific publications

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Authors : Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, Leleu X
Year : 2022
Journal : Leukemia
Volume : 36
Pages : 881-884

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Authors : Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, Van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M
Year : 2022
Journal : Cancer
Volume : 128
Pages : 1004-1014

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Authors : Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, Maerevoet M, Fruchart C, Snauwaert S, Le Gouill S, Marolleau JP, Molina L, Moluçon-Chabrot C, Thieblemont C, Tilly H, Bijou F, Haioun C, Van Den Neste E, Fabiani B, Meignan M, Cartron G, Salles G, Casasnovas O, Morschhauser F
Year : 2022
Journal : Blood
Volume : 139
Pages : 2338-2346

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Authors : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3

Polypoid colon mucosa in a leukemia patient.

Authors : Lifrange F, Van Gossum A, Verset L, Bron D, Gomez-Galdon M, Demetter P
Year : 2022
Journal : Acta Gastroenterol Belg
Volume : 85
Pages : 118-119